Adocia
Clinical-stage biotech developing novel formulations for metabolic diseases.
ADOC | PA
Overview
Corporate Details
- ISIN(s):
- FR0011184241 (+1 more)
- LEI:
- 969500ZL79KYH9PTYP78
- Country:
- France
- Address:
- 115 AVENUE LACASSAGNE, 69003 LYON
- Website:
- https://www.adocia.com
- Sector:
- Real estate activities
Description
Adocia is a clinical-stage biotechnology company that specializes in developing innovative treatments for metabolic diseases, with a primary focus on diabetes and obesity. The company's core expertise is the development of novel formulations of approved peptides, proteins, and metabolic hormones, such as insulin, to improve their therapeutic efficacy. Adocia leverages proprietary technology platforms to create a pipeline of specialty products. Its research also extends to novel cell therapy approaches, including an immunoprotective scaffold for cell delivery. The company's business model involves advancing its product candidates to clinical proof-of-concept before licensing them to partners for late-stage development and commercialization.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2025-12-18 18:00 |
Informations privilégiées / Autres communiqués
|
French | PDF • 346.3 KB | ||
| 2025-12-18 18:00 |
Inside Information / Other news releases
|
English | PDF • 345.4 KB | ||
| 2025-12-16 16:46 |
Franchissement de seuil
|
French | PDF • 120.9 KB | ||
| 2025-12-15 11:02 |
Franchissement de seuils
|
French | PDF • 109.5 KB | ||
| 2025-12-08 19:30 |
Inside Information / Other news releases
|
English | PDF • 463.2 KB | ||
| 2025-12-08 19:30 |
Informations privilégiées / Autres communiqués
|
French | PDF • 491.1 KB | ||
| 2025-12-04 07:30 |
Informations privilégiées / Autres communiqués
|
French | PDF • 774.3 KB | ||
| 2025-12-04 07:30 |
Inside Information / Other news releases
|
English | PDF • 822.6 KB | ||
| 2025-11-14 18:00 |
Inside Information / Other news releases
|
English | PDF • 463.2 KB | ||
| 2025-11-14 18:00 |
Informations privilégiées / Autres communiqués
|
French | PDF • 491.3 KB | ||
| 2025-11-12 07:30 |
Inside Information / Other news releases
|
English | PDF • 511.9 KB | ||
| 2025-11-12 07:30 |
Informations privilégiées / Autres communiqués
|
French | PDF • 511.5 KB | ||
| 2025-10-21 10:42 |
Franchissement de seuils
|
French | PDF • 109.0 KB | ||
| 2025-10-15 18:00 |
Informations privilégiées / Communiqué sur comptes, résultats
|
French | PDF • 558.9 KB | ||
| 2025-10-15 18:00 |
Inside Information / News release on accounts, results
|
English | PDF • 574.4 KB |
Automate Your Workflow. Get a real-time feed of all Adocia filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Adocia
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Adocia via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-03-21 | N/A | Other | Buy | 51,921 | 499,999.23 EUR |
| 2024-03-21 | N/A | Other | Buy | 15,576 | 149,996.88 EUR |
| 2023-12-29 | N/A | Other | Sell | 20,000 | 236,550.00 EUR |
| 2023-10-05 | N/A | Other | Sell | 50,000 | 400,000.00 EUR |
| 2023-09-20 | N/A | Other | Sell | 36,240 | 291,376.85 EUR |
| 2023-07-28 | N/A | Other | Buy | 220,264 | 999,998.56 EUR |
| 2023-07-28 | N/A | Other | Buy | 110 | 499.40 EUR |
Peer Companies
